Eglin Pharma Wins Two Prestigious Awards at STIF International Sci-Tech Innovation Festival

Recently, the STIF 6th International Science and Technology Innovation Festival & 2025 Intelligent China Leadership Summit, themed "Digital-Driven, Smart Manufacturing for the Future," was held in Beijing. At this industry event focused on technological innovation and new quality productivity, Evergreen Therapeutics won accolades for its breakthroughs in AI-driven drug development and the leadership influence of its founder and chairman, Dr. Tao Du, in the AI pharmaceuticals industry."2025 Annual AI Innovation Application Award"And"AI Leader of the Year 2025"Two Major Honors.

The STIF International Science and Technology Innovation Festival, established in 2020, is one of the most influential annual events in the fields of technological innovation and new quality productive forces. It aims to comprehensively showcase scientific and technological innovation achievements and convey the spirit of innovation by building a diverse and open platform for exchange and cooperation.This year's Science and Technology Innovation Festival has attracted more than 200 leading technology companies and high-growth brands with new productive forces from around the globe. Over 120 distinguished guests from international organizations, government departments, top research institutions, and leading enterprises shared cutting-edge strategic insights and practical perspectives at the event, gathering more than 1,000 participants from the fields of technological innovation, new productive forces, and digital intelligence.

Evergreen Therapeutics' AI platform, which won an award, deeply integrates multi-omics, clinical, and real-world data. Utilizing artificial intelligence technology, it achieves an "end-to-end closed loop" from target discovery to clinical validation through core engines such as cross-species translational prediction and mechanism prioritization. This provides the industry with a replicable and efficient drug development paradigm. EG-501, a core pipeline developed using this self-developed platform, has announced positive Phase II clinical trial results, demonstrating significant potential as the first therapy for cognitive impairment in neuropsychiatric systemic lupus erythematosus. Currently, the company has six pipelines approved by the U.S. FDA to enter clinical trials, making it one of the fastest AI-driven pharmaceutical enterprises in China to advance into the later stages of clinical development.

Dr. Tao Du, Founder and Chairman of Evergreen Therapeutics, has been awarded the "AI Leader of the Year" at this year's Science and Technology Innovation Festival for his deep expertise and contributions in the AI-driven pharmaceutical field. Dr. Du expressed that the two accolades not only serve as an encouragement for his continued dedication to AI drug discovery but also signify high recognition of Evergreen Therapeutics' technological innovation and industry contributions. Moving forward, the company will continue to leverage its multidisciplinary expert team and proprietary AI drug discovery platform, actively collaborating with industry partners to deepen synergistic cooperation, thereby fostering the development and implementation of new productive forces in the pharmaceutical field.